Ray Dalio’s Ginkgo Bioworks DNA Stock Holding History

Ray Dalio’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-8,849	Closed	-$842K	–	905
2022 Q2	$842K	Buy	+8,849	New	+$1.08M	﹤0.01%	818

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Ray Dalio's DNA Position: Q3 2022 in Review

Ray Dalio sold out of Ginkgo Bioworks (DNA) in Q3 2022, closing a stake of 8,849 shares — an estimated $842K sold.

Ray Dalio first reported a position in DNA in Q2 2022 and held it in 1 quarter. The position peaked at $842K in Q2 2022. 278 funds tracked by Wall St. Rank hold DNA as of Q3 2022.

Ray Dalio reported no remaining Ginkgo Bioworks position as of Q3 2022 after selling out during the quarter.
Ray Dalio sold 8,849 Ginkgo Bioworks shares in Q3 2022, an estimated $842K.
Ray Dalio first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 1 quarter.
Ray Dalio's Ginkgo Bioworks position peaked at $842K in Q2 2022.
278 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2022.

Based on Bridgewater Associates's 13F filing for Q3 2022, filed 10 Nov 2022.